Targeting KRAS mutant cancers: from druggable therapy to drug resistance
文献类型：期刊论文
| 作者 | Zhu, Chunxiao6,7; Guan, Xiaoqing5,7; Zhang, Xinuo4,7; Luan, Xin2,3; Song, Zhengbo7; Cheng, Xiangdong5,7; Zhang, Weidong1,2,3; Qin, Jiang-Jiang5,6,7 |
| 刊名 | MOLECULAR CANCER
 |
| 出版日期 | 2022-08-04 |
| 卷号 | 21 |
| 关键词 | KRAS mutations Druggable Resistance Combination therapy |
| DOI | 10.1186/s12943-022-01629-2 |
| 通讯作者 | Cheng, Xiangdong(chengxd@zjcc.org.cn) ; Zhang, Weidong(wdzhangy@hotmail.com) ; Qin, Jiang-Jiang(jqin@ucas.ac.cn) |
| 英文摘要 | Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with drugs is challenging because KRAS is considered undruggable due to the lack of classic drug binding sites. Over the past 40 years, great efforts have been made to explore routes for indirect targeting of KRAS mutant cancers, including KRAS expression, processing, upstream regulators, or downstream effectors. With the advent of KRAS (G12C) inhibitors, KRAS mutations are now druggable. Despite such inhibitors showing remarkable clinical responses, resistance to monotherapy of KRAS inhibitors is eventually developed. Significant progress has been made in understanding the mechanisms of drug resistance to KRAS-mutant inhibitors. Here we review the most recent advances in therapeutic approaches and resistance mechanisms targeting KRAS mutations and discuss opportunities for combination therapy. |
| WOS关键词 | COLONY-STIMULATING FACTOR ; ACQUIRED-RESISTANCE ; LUNG ADENOCARCINOMA ; PI3K INHIBITORS ; MEK INHIBITION ; PHASE-II ; RAS ; EGFR ; KINASE ; RECEPTOR |
| 资助项目 | Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province[2022E10021] ; Medical Science and Technology Project of Zhejiang Province[WKJ-ZJ-2202] ; Program of Zhejiang Provincial TCM Sci-tech Plan[2020ZZ005] ; National Key R&D Program of China[2021YFA0910100] ; Shanghai Frontiers Science Center of TCM Chemical Biology, and Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine[ZYYCXTD-D-202004] |
| WOS研究方向 | Biochemistry & Molecular Biology ; Oncology |
| 语种 | 英语 |
| WOS记录号 | WOS:000835692300001 |
| 出版者 | BMC |
| 资助机构 | Key Laboratory of Prevention, Diagnosis and Therapy of Upper Gastrointestinal Cancer of Zhejiang Province ; Medical Science and Technology Project of Zhejiang Province ; Program of Zhejiang Provincial TCM Sci-tech Plan ; National Key R&D Program of China ; Shanghai Frontiers Science Center of TCM Chemical Biology, and Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/132192]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 通讯作者 | Cheng, Xiangdong; Zhang, Weidong; Qin, Jiang-Jiang |
| 作者单位 | 1.Second Mil Med Univ, Sch Pharm, Shanghai 200433, Peoples R China 2.Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Shanghai 201203, Peoples R China 3.Shanghai Univ Tradit Chinese Med, Inst Interdisciplinary Integrat Med Res, Shanghai 201203, Peoples R China 4.Zhejiang Univ Technol, Coll Pharmaceut Sci, Hangzhou 310032, Peoples R China 5.Key Lab Prevent Diag & Therapy Upper Gastrointest, Hangzhou 310022, Peoples R China 6.UCAS, Hangzhou Inst Adv Study, Sch Mol Med, Hangzhou 310024, Peoples R China 7.Univ Chinese Acad Sci, Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc IBMC,Canc Hosp, Hangzhou 310022, Peoples R China |
| 推荐引用方式 GB/T 7714 | Zhu, Chunxiao,Guan, Xiaoqing,Zhang, Xinuo,et al. Targeting KRAS mutant cancers: from druggable therapy to drug resistance[J]. MOLECULAR CANCER,2022,21. |
| APA | Zhu, Chunxiao.,Guan, Xiaoqing.,Zhang, Xinuo.,Luan, Xin.,Song, Zhengbo.,...&Qin, Jiang-Jiang.(2022).Targeting KRAS mutant cancers: from druggable therapy to drug resistance.MOLECULAR CANCER,21. |
| MLA | Zhu, Chunxiao,et al."Targeting KRAS mutant cancers: from druggable therapy to drug resistance".MOLECULAR CANCER 21(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。